Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | FGF1 | P05230 | 1/20 | 0.31 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.30 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.30 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12360822 | 1.00 | LGALS8 (0.36) | LGALS8OGAFGF1SSTR5SSTR1 | |
| SCHEMBL13513423 | 1.00 | LGALS8 (0.36) | LGALS8OGAFGF1SSTR5SSTR1 | |
| SCHEMBL27393414 | 1.00 | LGALS8 (0.36) | LGALS8OGAFGF1SSTR5SSTR1 | |
| SCHEMBL22096076 | 1.00 | LGALS8 (0.36) | LGALS8OGAFGF1SSTR5SSTR1 | |
| SCHEMBL13513424 | 0.87 | — | — | |
| SCHEMBL12360821 | 0.87 | — | — | |
| SCHEMBL22699770 | 0.85 | OGA (0.32) | LGALS8OGA | |
| SCHEMBL14537231 | 0.85 | FGF1 (0.31) | LGALS8OGAFGF1 | |
| SCHEMBL24931089 | 0.84 | OGA (0.34) | LGALS8OGASSTR5SSTR1SSTR2 | |
| SCHEMBL15691431 | 0.82 | LGALS8 (0.50) | LGALS8OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211743-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-07-07 | — | — | US | disclosed |
| US-9629867-B2 | Methods and compositions of improved modified siRNA | AM Biotechnologies, Inc. (US) | 2017-04-25 | — | — | US | disclosed |
| US-7994152-B2 | Method of treating a cancer by administering A 2′,5′-oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7651999-B2 | phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer | SANKYO COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211743-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | SLC2A8, IGF2BP2, SLC2A2 | LGALS8 644/4885OGA 99/4885FGF1 1945/4885 |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | ADAR, NSUN2, ADORA3 | LGALS8 4615/4885OGA 108/4885FGF1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.